First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: A preliminary report

Charles Vogel, M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. Stewart

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin® (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression.

Original languageEnglish
JournalEuropean Journal of Cancer
Volume37
Issue numberSUPPL. 1
StatePublished - Feb 22 2001

Fingerprint

Breast Neoplasms
Disease Progression
Research Personnel
Safety
Drug Therapy
Trastuzumab
Therapeutics

Keywords

  • Clinical trial
  • Efficacy
  • First-line
  • Herceptin® (trastuzumab)
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Vogel, C., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., ... Stewart, S. J. (2001). First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: A preliminary report. European Journal of Cancer, 37(SUPPL. 1).

First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer : A preliminary report. / Vogel, Charles; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.

In: European Journal of Cancer, Vol. 37, No. SUPPL. 1, 22.02.2001.

Research output: Contribution to journalArticle

Vogel, C, Cobleigh, MA, Tripathy, D, Gutheil, JC, Harris, LN, Fehrenbacher, L, Slamon, DJ, Murphy, M, Novotny, WF, Burchmore, M, Shak, S & Stewart, SJ 2001, 'First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: A preliminary report', European Journal of Cancer, vol. 37, no. SUPPL. 1.
Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer: A preliminary report. European Journal of Cancer. 2001 Feb 22;37(SUPPL. 1).
Vogel, Charles ; Cobleigh, M. A. ; Tripathy, D. ; Gutheil, J. C. ; Harris, L. N. ; Fehrenbacher, L. ; Slamon, D. J. ; Murphy, M. ; Novotny, W. F. ; Burchmore, M. ; Shak, S. ; Stewart, S. J. / First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer : A preliminary report. In: European Journal of Cancer. 2001 ; Vol. 37, No. SUPPL. 1.
@article{b8bd4428b7e3480b954c1bc9e6ad8ff5,
title = "First-line, single-agent Herceptin{\circledR} (trastuzumab) in metastatic breast cancer: A preliminary report",
abstract = "Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin{\circledR} (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15{\%} according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23{\%} based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression.",
keywords = "Clinical trial, Efficacy, First-line, Herceptin{\circledR} (trastuzumab), Metastatic breast cancer",
author = "Charles Vogel and Cobleigh, {M. A.} and D. Tripathy and Gutheil, {J. C.} and Harris, {L. N.} and L. Fehrenbacher and Slamon, {D. J.} and M. Murphy and Novotny, {W. F.} and M. Burchmore and S. Shak and Stewart, {S. J.}",
year = "2001",
month = "2",
day = "22",
language = "English",
volume = "37",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "SUPPL. 1",

}

TY - JOUR

T1 - First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancer

T2 - A preliminary report

AU - Vogel, Charles

AU - Cobleigh, M. A.

AU - Tripathy, D.

AU - Gutheil, J. C.

AU - Harris, L. N.

AU - Fehrenbacher, L.

AU - Slamon, D. J.

AU - Murphy, M.

AU - Novotny, W. F.

AU - Burchmore, M.

AU - Shak, S.

AU - Stewart, S. J.

PY - 2001/2/22

Y1 - 2001/2/22

N2 - Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin® (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression.

AB - Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin® (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer who had relapsed after one or two chemotherapy regimens for their metastatic disease. The results showed a positive and durable overall response rate (15% according to a response evaluation committee (REC) assessment) using trastuzumab monotherapy (initial dose 4 mg/kg intravenously (i.v.) followed by 2 mg/kg i.v. weekly). In another recently completed phase II trial, 113 patients were randomised to two dose levels (initial dose of 4 mg/kg i.v. dose followed by 2 mg/kg i.v. weekly, or initial dose of 8 mg/kg followed by 4 mg/kg i.v. weekly) of single-agent trastuzumab as first-line therapy for metastatic disease. The preliminary overall response rate was 23% based on investigator assessment, and tolerability was excellent as in previous trials; efficacy was similar in both dose groups, but the side-effects tended to be more frequent in the higher dose group. The preferred dosage is therefore the same as that currently recommended, i.e. an initial dose of 4 mg/kg i.v. followed by 2 mg/kg weekly i.v. until disease progression.

KW - Clinical trial

KW - Efficacy

KW - First-line

KW - Herceptin® (trastuzumab)

KW - Metastatic breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0035129498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035129498&partnerID=8YFLogxK

M3 - Article

C2 - 11167088

AN - SCOPUS:0035129498

VL - 37

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - SUPPL. 1

ER -